Findings

What do systematic reviews say?

14 questions · 14 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 21.4%GRADE not reported 0 · 0%Very low 5 · 35.7%Low 3 · 21.4%Moderate 3 · 21.4%High 0 · 0%

Hydroxyurea vs observation

Pain alteration · adults and children with sickle cell disease and an increased risk of stroke

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydroxyurea vs observation

Life‐threatening illness · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs observation

Death during the study · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs observation

Measures of HbF · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs observation

Measures of ANC · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs observation

Quality of life · adults and children with sickle cell disease and an increased risk of stroke

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydroxyurea vs observation

Adverse events or toxicity: differences in rates of specific adverse events · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

All‐cause mortality · adults and children with sickle cell disease and an increased risk of stroke

Summary of findings ‐ Hydroxyurea and phlebotomy showed no clear difference in death during the study (all deaths) compared with transfusion and chelation (low certainty).

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
RR 0.99 [0.06, 15.42]
2 studies · 254 participants
Low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Measures of HbF · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 254 participants
Moderate

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Measures of ANC · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 254 participants
Moderate

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Quality of life · adults and children with sickle cell disease and an increased risk of stroke

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Adverse events or toxicity: differences in rates of specific adverse events · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 254 participants
Low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Pain alteration: proportion experiencing serious VOC or sickle‐related pain events · adults and children with sickle cell disease and an increased risk of stroke

Summary of findings ‐ Hydroxyurea and phlebotomy may leads to higher pain alteration: proportion experiencing serious VOC or… compared with transfusion and chelation (low certainty).

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
RR 3.37 [1.59, 7.11]
2 studies · 254 participants
Low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Life‐threatening illness · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 254 participants
Moderate